Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SSPKU - Silver Spike Acquisition Corp - Units (1 Ord Share Class A & 1/2 War)


Previous close
22.99
0   0%

Share volume: 0
Last Updated: Fri 11 Jun 2021 06:00:00 AM CEST
Software Publishers: 2.37%

PREVIOUS CLOSE
CHG
CHG%

$22.99
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
16%
Profitability 0%
Dept financing 22%
Liquidity 50%
Performance 21%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$22.99
P/E Ratio 
0.00
DAY RANGE
$21.38 - $23.58
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
472.973 M
YIELD 
N/A
SHARES OUTSTANDING 
25.000 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO:
Region: US
Website: www.silverspikecap.com/sspk-spac
Employees: 0
IPO year: -
Issue type:
Market: NASDAQ
Industry: Software Publishers
Sector: Information

Silver Spike Acquisition Corp. (SSAC), an affiliate of Silver Spike Capital, is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The management team and board of directors are composed of veteran cannabis and finance industry executives and founders, including Scott Gordon, founder, and CEO of the Company, who began investing in the cannabis industry in 2014 and in 2016 co-founded and became Chairman of Egg Rock Holdings, the parent company of the Papa & Barkley family of cannabis products with related subsidiary assets in manufacturing, processing and logistics; and Dr. Orrin Devinsky, director of the Company, who is the director of the NYU Langone Comprehensive Epilepsy Center and is a Professor of Neurology, Neuroscience, Psychiatry, and Neuroscience at the NYU School of Medicine and who, since 2016 has served as the Chair of the Medical Advisory Board at Tilray, a pharmaceutical and cannabis company.

Recent news